• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol. Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing

tetano

Editor, Senior Moderator
J Med Virol. 2020 Mar 21. doi: 10.1002/jmv.25783. [Epub ahead of print]
Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing.


Wan S[SUP]1[/SUP], Xiang Y[SUP]1,[/SUP][SUP]2[/SUP], Fang W[SUP]1[/SUP], Zheng Y[SUP]3[/SUP], Li B[SUP]1[/SUP], Hu Y[SUP]1[/SUP], Lang C[SUP]1,[/SUP][SUP]4[/SUP], Huang D[SUP]1[/SUP], Sun Q[SUP]1[/SUP], Xiong Y[SUP]1,[/SUP][SUP]5[/SUP], Huang X[SUP]1,[/SUP][SUP]6[/SUP], Lv J[SUP]1,[/SUP][SUP]7[/SUP], Luo Y[SUP]8[/SUP], Shen L[SUP]1[/SUP], Yang H[SUP]1[/SUP], Huang G[SUP]1[/SUP], Yang R[SUP]1[/SUP].

Author information




Abstract

BACKGROUND:

The outbreak of the novel coronavirus in China (SARS CoV-2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease.
METHODS:

Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study.
RESULTS:

A total of 135 hospitalized patients with COVID-19 were enrolled. The median age was 47 years (IQR 36-55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty-three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest CT scans showed bilateral patchy shadows or ground glass opacity in the lungs of all of the patients. All of the patients received antiviral therapy (135 [100%] (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of western and Chinese medicine. Compared with the mild cases, the severe cases had lower lymphocyte counts and higher plasma levels of Pt, APTT, D-dimer, LDH, PCT, ALB, CRP, and AST.
CONCLUSION:

In this study, the clinic features and therapies of 135 COVID-19 patients were demonstrated. Kaletra and traditional Chinese medicine played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and traditional Chinese medicine in the treatment of COVID-19. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.



KEYWORDS:

COVID-19; Clinical Features; Cognition; Northeast Chongqing; Treatment


PMID:32198776DOI:10.1002/jmv.25783
 
Back
Top